Christopher Richard Anzalone Sells 11,520 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Christopher Richard Anzalone sold 11,520 shares of the stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $19.05, for a total transaction of $219,456.00. Following the transaction, the chief executive officer now directly owns 3,764,252 shares in the company, valued at approximately $71,709,000.60. The trade was a 0.31 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Christopher Richard Anzalone also recently made the following trade(s):

• On Monday, December 23rd, Christopher Richard Anzalone sold 12,563 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $19.59, for a total transaction of $246,109.17.
• On Wednesday, December 18th, Christopher Richard Anzalone sold 26,712 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $21.24, for a total value of $567,362.88.

Arrowhead Pharmaceuticals Trading Down 1.5 %

Shares of ARWR stock traded down $0.29 during trading on Monday, hitting $19.50. 1,462,451 shares of the stock traded hands, compared to its average volume of 1,255,717. The firm has a market capitalization of $2.43 billion, a P/E ratio of -3.88 and a beta of 0.97. Arrowhead Pharmaceuticals, Inc. has a 52-week low of $17.05 and a 52-week high of $39.83. The company has a debt-to-equity ratio of 2.06, a current ratio of 6.74 and a quick ratio of 6.74. The firm’s fifty day moving average price is $21.05 and its 200-day moving average price is $22.64.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

Several large investors have recently modified their holdings of the business. Commonwealth Equity Services LLC raised its holdings in Arrowhead Pharmaceuticals by 3.7% in the 2nd quarter. Commonwealth Equity Services LLC now owns 34,663 shares of the biotechnology company’s stock valued at $901,000 after buying an additional 1,250 shares during the period. Rhumbline Advisers lifted its holdings in shares of Arrowhead Pharmaceuticals by 2.9% in the 2nd quarter. Rhumbline Advisers now owns 383,029 shares of the biotechnology company’s stock worth $9,955,000 after acquiring an additional 10,924 shares during the last quarter. TD Asset Management Inc boosted its position in shares of Arrowhead Pharmaceuticals by 90.8% during the 2nd quarter. TD Asset Management Inc now owns 54,200 shares of the biotechnology company’s stock worth $1,409,000 after purchasing an additional 25,800 shares during the period. Victory Capital Management Inc. increased its holdings in Arrowhead Pharmaceuticals by 67.3% in the 2nd quarter. Victory Capital Management Inc. now owns 41,090 shares of the biotechnology company’s stock valued at $1,068,000 after purchasing an additional 16,534 shares during the last quarter. Finally, Arizona State Retirement System raised its position in Arrowhead Pharmaceuticals by 2.4% in the second quarter. Arizona State Retirement System now owns 34,685 shares of the biotechnology company’s stock valued at $901,000 after purchasing an additional 821 shares during the period. Institutional investors and hedge funds own 62.61% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. Chardan Capital reaffirmed a “buy” rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Thursday, December 12th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arrowhead Pharmaceuticals in a report on Monday, September 9th. StockNews.com upgraded shares of Arrowhead Pharmaceuticals to a “sell” rating in a research report on Friday, December 20th. HC Wainwright restated a “buy” rating and set a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Friday, December 20th. Finally, Citigroup cut their price objective on shares of Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Wednesday, November 27th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $43.33.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.